Clincosm LogoSign in Get a demo

Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer

Sponsor
Fudan University (Other)
Overall Status
Completed
CT.gov ID
NCT06040021
Collaborator
(none)
15,244
Enrollment
185.9
Actual Duration (Months)

Study Details

Study Description

Brief Summary

The clinical and pathological features of early-onset colorectal cancer (EOCRC) differ from those of late-onset colorectal cancer (LOCRC). Our research aims to thoroughly elucidate the distinctions between them by analyzing clinical prognosis, metastatic patterns, gene expression, and genomic mutation profiles. Our deliberation will uncover latent strategies for personalized therapeutic of both EOCRC and LOCRC.

Condition or Disease Intervention/Treatment Phase
  • Other: standardized treatment

Study Design

Study Type:
Observational
Actual Enrollment :
15244 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Integrated Analysis of Multi-center Cohorts and Bulk RNA-sequencing Data Reveal Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer
Actual Study Start Date :
Jan 1, 2008
Actual Primary Completion Date :
Dec 31, 2018
Actual Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
EOCRC

Patients aged<50 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.

Other: standardized treatment
Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
IOCRC

Patients aged between 50 to 70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.

Other: standardized treatment
Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
LOCRC

Patients aged between≄70 with colorectal cancer between 2008 and 2018 in Fudan university Shanghai cancer center.

Other: standardized treatment
Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.

Outcome Measures

Primary Outcome Measures

  1. OS [5 years after intervention]

    overall survival

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 95 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • The initial diagnosis of colonoscopy and pathology belongs to colorectal cancer;

  • Patients should sign an informed consent form after fully understanding the purpose, procedures and potential risks of the study, indicating their voluntary participation in the research.

Exclusion Criteria:

  • Patients with obvious local or systemic severe infection;

  • Acute abdomen: intestinal obstruction, peritonitis, intestinal perforation;

  • Have a systemic underlying disease that has not been controlled, or is unstable;

  • Patients with poor physical fitness or serious other organic diseases who cannot tolerate anesthesia and surgery;

  • Women during pregnancy, perinatal and lactation;

  • Patients with severe mental disorders (such as schizophrenia, bipolar disorder, etc.) or patients who are mentally incapable or unable to understand the requirements for participation in the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Fudan University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
LI XIN-XIANG, Professor, Fudan University
ClinicalTrials.gov Identifier:
NCT06040021
Other Study ID Numbers:
  • FDU-EOCRC
First Posted:
Sep 15, 2023
Last Update Posted:
Sep 15, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Colorectal Neoplasms

Study Results

No Results Posted as of Sep 15, 2023